Aims Clot waveform analysis (CWA) has been reported to extend the interpretation of clotting time measurement. The parameters obtained from successive derivatives of the clotting reaction curves reflect the rates of activation of individual coagulation factors, theoretically dissecting the cascade pathway. This study aims to assess the in vitro effects of direct thrombin inhibitors (DTIs) and activated factor X (FXa) inhibitors. Methods CWA was applied to the activated partial thromboplastin time (APTT) assay of plasma samples spiked with each drug. For CWA of APTT measurement curves (APTT-CWA), the positive mode of clotting reaction curves was defined as the direction towards fibrin generation. Results All the maximum positive values in the successive derivatives were decreased dependently on the concentrations of each drug. Moreover, the negative values in the second and third derivatives appeared putatively due to consumption of thrombin and factor FXa, respectively, to form complexes with plasma serine protease inhibitors. The decrease of the maximum negative values observed dependently on the concentrations of each drug appeared to be consistent with the decreased generation of thrombin and factor FXa. The analysis of Hill coefficients of each drug in the dose–response of changes in the APTT-CWA parameters revealed a difference in anticoagulant cooperativity between DTIs versus FXa inhibitors. Conclusions The APTT-CWA demonstrated evidence for the blockade of thrombin-positive feedback by DTIs and FXa inhibitors and that for the differences in anticoagulant cooperativity between them. The results demonstrate the usability of CWA for assessment of anticoagulation and provide insights into direct anticoagulants.
Aims: Bivalent direct thrombin inhibitors (DTIs), hirudin and bivalirudin, bind to the active site and exosite 1 of thrombin irreversibly and reversibly, respectively. The present study aims to assess in vitro effects of hirudin and bivalirudin through clot waveform analysis (CWA) and enzyme kinetics in coagulation assays. Methods: The pooled normal plasma and its dilutions were spiked with hirudin or bivalirudin. The activated partial thromboplastin time (APTT) assay and the Clauss fibrinogen assay were performed using the CS-5100 (Sysmex). The APTT-CWA data were automatically gained by the CS-5100 programme. Results: In APTT-CWA, the maximum coagulation velocity, acceleration and deceleration were decreased dependently on the drug concentrations, demonstrating evidence for the blockade of thrombin-positive feedback by hirudin or bivalirudin. The Hill plot analysis was applied to the dose-dependent curves in bivalirudin. The Hill coefficients were greater than 1, showing positive anticoagulant cooperativity. Regarding the dose-dependent curves in hirudin, all the parameters dropped to almost zero without making an asymptotic line. In the Clauss fibrinogen assay, the Lineweaver-Burk plots demonstrated that both drugs exhibit mixed inhibition mimicking uncompetitive binding. The Dixon plots in bivalirudin were linear and supported the inhibition type described above. The Dixon plots in hirudin were non-linear and inappropriate to use for determination of the inhibition type. In addition, the inverse function of the clotting time appeared to drop to zero without making an asymptotic line, suggesting complete loss of thrombin activity by irreversible binding. Conclusions: The results provide insights into anticoagulation with bivalent DTIs.
20 February 2020 in International Journal of Laboratory Hematology
The intestinal local absorption and the hepatic local disposition of 5-fluorouracil (5-FU) in a single conscious rat was investigated by the simultaneous sampling of portal and systemic bloods (PS method). The portal blood flow rate, measured using a compact electromagnetic flow-meter, was estimated to be 15.3 +/- 2.2 ml/min per body weight (250g). The portal vein and the femoral artery of the rat were cannulated to simultaneously obtain blood samples from two sites. 5-FU (30 mg/kg) was administered first intraarterially, and subsequently orally 90 min after intraarterial administration to a single conscious rat (short-period double dosing; DD). Concentrations of 5-FU in the portal and arterial bloods were determined by HPLC. The local absorption ratio (Fa) and the absolute bioavailability (F) were 71.2 +/- 15.4 and 25.1 +/- 13.2%, respectively. Consequently, the hepatic extraction ratio (F[H] = F/Fa) was estimated to be 34.9 +/- 14.4%. The mean local absorption time (t[a]) and the mean absorption time (MAT) were 37.5 +/- 15.5 and 31.4 +/- 13.7 min, respectively and they were statistically the same. In conclusion, a PS method by short-period double dosing (PS-DD method) has been developed to evaluate the first-pass effect, separating the intestinal absorption and hepatic elimination of a drug in a single conscious rat. It was demonstrated by applying PS-DD method that the low bioavailability of 5-FU can be explained by the large hepatic first-pass extraction, and that the large inter-individual variation in bioavailability of 5-FU is caused mainly by a large variation in the hepatic first-pass effect. The large variation in t(a) (or MAT) was predicted to be due to a variation in the gastric emptying time.